BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19692247)

  • 1. Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization.
    Tasler S; Müller O; Wieber T; Herz T; Pegoraro S; Saeb W; Lang M; Krauss R; Totzke F; Zirrgiebel U; Ehlert JE; Kubbutat MH; Schächtele C
    Bioorg Med Chem; 2009 Sep; 17(18):6728-37. PubMed ID: 19692247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors.
    Bhuva HA; Kini SG
    J Mol Graph Model; 2010 Aug; 29(1):32-7. PubMed ID: 20493747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
    Coumar MS; Chu CY; Lin CW; Shiao HY; Ho YL; Reddy R; Lin WH; Chen CH; Peng YH; Leou JS; Lien TW; Huang CT; Fang MY; Wu SH; Wu JS; Chittimalla SK; Song JS; Hsu JT; Wu SY; Liao CC; Chao YS; Hsieh HP
    J Med Chem; 2010 Jul; 53(13):4980-8. PubMed ID: 20550212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
    Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
    J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicomplex-based pharmacophore-guided 3D-QSAR studies of N-substituted 2'-(aminoaryl)benzothiazoles as Aurora-A inhibitors.
    He G; Qiu M; Li R; Ouyang L; Wu F; Song X; Cheng L; Xiang M; Yu L
    Chem Biol Drug Des; 2012 Jun; 79(6):960-71. PubMed ID: 22381081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
    Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of new fluorescent xanthines as kinase inhibitors.
    Kim D; Jun H; Lee H; Hong SS; Hong S
    Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro antiproliferative activities and kinase inhibitory potencies of glycosyl-isoindigo derivatives.
    Sassatelli M; Bouchikhi F; Aboab B; Anizon F; Fabbro D; Prudhomme M; Moreau P
    Anticancer Drugs; 2007 Oct; 18(9):1069-74. PubMed ID: 17704657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
    Steiner L; Blum G; Friedmann Y; Levitzki A
    Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
    Zhang Q; Xia Z; Mitten MJ; Lasko LM; Klinghofer V; Bouska J; Johnson EF; Penning TD; Luo Y; Giranda VL; Shoemaker AR; Stewart KD; Djuric SW; Vasudevan A
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7615-22. PubMed ID: 23103095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
    Kim KH; Wissner A; Floyd MB; Fraser HL; Wang YD; Dushin RG; Hu Y; Olland A; Guo B; Arndt K
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5225-8. PubMed ID: 19628388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative and protein kinase binding activities of Some N6, 5'-bis-ureido 5'-amino-5'-deoxyadenosine derivatives.
    Peterson MA; Oliveira M; Christiansen MA
    Nucleosides Nucleotides Nucleic Acids; 2009 May; 28(5):394-407. PubMed ID: 20183591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.